Thursday, 15 October 2026European Markets

EASE2PAY NV Stock Went Down By Over 29% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of EASE2PAY NV (AEX-Index: EAS2P.AS) fell by a staggering 29.58% in 21 sessions from €1.14 to €0.80 at 17:07 EST on Monday, after five sequential sessions in a row of losses. AEX-Index is rising 0.2% to €763.71, after two successive sessions in a row of gains.

EASE2PAY NV's last close was €0.86, 68.61% under its 52-week high of €2.74.

About EASE2PAY NV

Ease2pay N.V. provides online payment services and platform in the Netherlands. It offers payment transaction platform, which offers users services to order and pay in one action and parking solutions. The company was formerly known as DOCDATA N.V. and changed its name to Ease2pay N.V. in February 2018. Ease2pay N.V. is headquartered in Waalwijk, the Netherlands. Ease2pay N.V. is a subsidiary of The Internet of Cars V.O.F.

Earnings Per Share

As for profitability, EASE2PAY NV has a trailing twelve months EPS of €-0.09.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -9.6%.

Volatility

EASE2PAY NV's last week, last month's, and last quarter's current intraday variation average was a negative 4.44%, a negative 1.88%, and a positive 2.41%.

EASE2PAY NV's highest amplitude of average volatility was 4.44% (last week), 2.10% (last month), and 2.41% (last quarter).

More news about EASE2PAY NV (EAS2P.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
EASE2PAY NV Stock Went Down By Over 29% In The Last 21 Sessions | ViaNews EU